Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6646 to 6660 of 7680 results

  1. Ridaforolimus for the maintenance treatment of metastatic soft tissue or bone sarcoma [ID415]

    Discontinued [GID-TAG431]

    Technology appraisal guidance
    Discontinued

  2. Nivolumab for previously treated gastric or gastro-oesophageal junction cancer [ID1118]

    Discontinued [GID-TA10151]

    Technology appraisal guidance
    Discontinued

  3. Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma [ID1305]

    Discontinued [GID-TA10244]

    Technology appraisal guidance
    Discontinued

  4. Nivolumab with radiation therapy for previously untreated glioblastoma multiforme [ID1562]

    Discontinued [GID-TA10443]

    Technology appraisal guidance
    Discontinued

  5. Gastroenteropancreatic neuroendocrine tumours (somatostatin, non-progressive) - lutetium-177 DOTATATE [ID857]

    Discontinued [GID-TA10033]

    Technology appraisal guidance
    Discontinued

  6. Etirinotecan pegol for treating breast cancer with brain metastases [ID881]

    Discontinued [GID-TA10066]

    Technology appraisal guidance
    Discontinued

  7. Pazopanib for the second line treatment of advanced and/or metastatic renal cell carcinoma [ID70]

    Discontinued [GID-TAG398]

    Technology appraisal guidance
    Discontinued

  8. Biotin for treating primary and secondary progressive multiple sclerosis [ID919]

    Discontinued [GID-TA10099]

    Technology appraisal guidance
    Discontinued

  9. Autologous haematopoietic stem cell transplantation for treating multiple sclerosis [ID1111]

    Discontinued [GID-TA10306]

    Technology appraisal guidance
    Discontinued

  10. Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]

    In development [GID-TA11022] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. The MAGEC system for spinal lengthening in children with scoliosis (MT169)

    Discontinued [GID-MT544]

    Medical technologies guidance
    Discontinued

  12. T-cell lymphoma (peripheral, relapsed or refractory) - romidepsin [ID504]

    Discontinued [GID-TAG433]

    Technology appraisal guidance
    Discontinued

  13. Diabetic foot ulcers - new treatments [ID381]

    Discontinued [GID-TAG371]

    Technology appraisal guidance
    Discontinued

  14. Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]

    In development [GID-TA10696] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously TKI-treated EGFR-positive metastatic non-squamous non-small-cell lung cancer [ID3873]

    In development [GID-TA10766] Expected publication date: TBC

    Technology appraisal guidance
    In development